XML 33 R27.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Financial Statement Details (Tables)

9 Months Ended

Sep. 30, 2025

Inventory Disclosure [Abstract]

Schedule of Other Current Assets

Other current assets consist of the following (in thousands):


		September 30, 2025				December 31, 2024
Prepaid research and development expenses		$	7,500			$	1,947
Interest and other non-trade receivables			1,289				1,609
Other prepaid expenses			2,360				2,510
Total other current assets		$	11,149			$	6,066

Schedule of Accrued Expenses

Accrued expenses consist of the following (in thousands):


		September 30, 2025				December 31, 2024
Accrued compensation		$	8,606			$	2,832
Accrued research and development expenses			12,084				14,453
Accrued contract termination costs			3,149				2,767
Other accrued expenses			4,755				9,920
Total accrued expenses		$	28,594			$	29,972

Schedule of Liability Related to Sale of Potential Future Royalties

The following is a reconciliation of the changes in our liabilities related to the sales of future royalties for the nine months ended September 30, 2025 (in thousands):


		Nine Months Ended September 30, 2025
		2012 Purchase and Sale Agreement				2020 Purchase and Sale Agreement				Total
Liabilities related to the sales of future royalties, net – beginning balance		$	7,197			$	84,579			$	91,776
Non-cash royalty revenue			(5,619	)			(27,506	)			(33,125	)
Non-cash interest expense			1,983				14,432				16,415
Amortization of transaction costs			—				98				98
Liabilities related to the sales of future royalties, net – ending balance		$	3,561			$	71,603			$	75,164